Breast Cancer Res Treat (2015) 154: 81.

Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli

Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk patients had a 10-year DMFS
of 87%.

Read more: Yao et al_2015_Breast Cancer Res Treat_Molecular Subtyping Improves Diagnostic Stratification…